Exelixis Q3 beats estimates on strong Cabometyx sales
FROM THE WIRE · FINANCE.YAHOO.COM
Exelixis EXEL reported better-than-expected results for the third quarter of 2026, with earnings and revenues surpassing the Zacks Consensus Estimate. Adjusted earnings per share (EPS) of 94 cents beat the Zacks Consensus Estimate of 89 cents. The company reported adjusted EPS…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishQuarterly results above consensus for a biotech company, with possible support for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Adjusted EPS was 94 cents versus 89 cents expected.
- 02Revenue rose 10.2% to $658.7 million.
- 03Growth was primarily driven by higher Cabometyx sales.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets